# Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

> **NCT03731442** · PHASE3 · RECRUITING · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 300 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **RADIATION:** Involved field irradiation
- **RADIATION:** Elective field irradiation
- **DRUG:** Paclitaxel
- **DRUG:** Platinum
- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT03731442
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731442, "Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03731442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*